Physician profile
Van Kaden Andre
NPI 1376002485
$3,863.61
in general payments reported to CMS, 2019-2025
8 companies · $480 in 2025
The $480 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,799 · 2024: $584 · 2025: $480.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,548 · Travel and Lodging: $1,316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,547.60 |
| Travel and Lodging | $1,316.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,989.62 | 2023-2025 | Durysta, Xen Glaucoma Treatment System |
| Alcon Vision LLC | $973.80 | 2023-2025 | Hydrus Microstent, Clareon, Centurion |
| Glaukos Corporation | $503.72 | 2023-2025 | Istent Infinite Trabecular Micro-Bypass System Model Is3, Iaccess Precision Blade, Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3 |
| Bausch & Lomb Americas INC. | $150.61 | 2023-2024 | Amvisc |
| Johnson & Johnson Surgical Vision, INC. | $117.34 | 2023-2024 | Tecnis Iol, Tecnis Simplicity, Veritas Vision System |
| Sight Sciences, INC. | $70.41 | 2024-2025 | Omni Surgical System |
| New World Medical,INC. | $34.77 | 2023-2025 | Kahook Dual Blade, Ahmed Glaucoma Valve, Streamline |
| Nova Eye, INC. | $23.34 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Van Andre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.